gene-corrected autologous hematopoietic stem cell therapy

Gene-corrected autologous hematopoietic stem cell therapy is an ex vivo gene therapy approach where a patient's own hematopoietic stem cells (HSCs) are harvested, genetically modified to correct a disease-causing mutation, and then re-infused into the patient. In the context of severe beta-thalassemia, this typically involves introducing a functional copy of the HBB gene or using gene editing to restore fetal hemoglobin production. The goal is to establish a permanent population of corrected erythroid progenitor cells that can produce functional hemoglobin, thereby alleviating the symptoms of anemia and reducing transfusion dependence. This specific program was associated with a clinical study sponsored by Dongguan Taixin Hospital in China.

Other names

gene-corrected autologous hematopoietic stem cell transplantation